BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 32310827)

  • 1. Identification of immunologic subtype and prognosis of GBM based on TNFSF14 and immune checkpoint gene expression profiling.
    Long S; Li M; Liu J; Yang Y; Li G
    Aging (Albany NY); 2020 Apr; 12(8):7112-7128. PubMed ID: 32310827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune Checkpoint Gene Expression Profiling Identifies Programmed Cell Death Ligand-1 Centered Immunologic Subtypes of Oral and Squamous Cell Carcinoma With Favorable Survival.
    Yu Y; Tang H; Franceschi D; Mujagond P; Acharya A; Deng Y; Lethaus B; Savkovic V; Zimmerer R; Ziebolz D; Li S; Schmalz G
    Front Med (Lausanne); 2021; 8():759605. PubMed ID: 35127742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of an immune checkpoint gene signature that accurately predicts prognosis and immunotherapy response in endometrial carcinoma.
    Li S; Dong C; Chen J; Gao X; Xie X; Zhang X
    Aging (Albany NY); 2021 Jun; 13(12):16696-16712. PubMed ID: 34158412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of immune subtypes and prognosis of hepatocellular carcinoma based on immune checkpoint gene expression profile.
    Xu D; Liu X; Wang Y; Zhou K; Wu J; Chen JC; Chen C; Chen L; Zheng J
    Biomed Pharmacother; 2020 Jun; 126():109903. PubMed ID: 32113055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishment and validation of an immune-based prognostic score model in glioblastoma.
    Qin Z; Zhang X; Chen Z; Liu N
    Int Immunopharmacol; 2020 Aug; 85():106636. PubMed ID: 32534425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive characterization of TNFSF14/LIGHT with implications in prognosis and immunotherapy of human gliomas.
    Han M; Sun Y; Zhao W; Xiang G; Wang X; Jiang Z; Xue Z; Zhou W
    Front Immunol; 2022; 13():1025286. PubMed ID: 36341396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
    Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
    J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of Tumor Antigens and Immune Subtypes of Glioblastoma for mRNA Vaccine Development.
    Lin H; Wang K; Xiong Y; Zhou L; Yang Y; Chen S; Xu P; Zhou Y; Mao R; Lv G; Wang P; Zhou D
    Front Immunol; 2022; 13():773264. PubMed ID: 35185876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Classification of Glioblastoma Associated with Immune Checkpoints and Tumor Microenvironment based on Immunogenomic Profiling.
    Zheng P; Zhang X; Ren D; Bai Q
    Neurol India; 2024 Mar; 72(2):297-303. PubMed ID: 38691473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of the sodium pump subunit ATP1A3 in glioma patients: Potential value in prognostic prediction and immunotherapy.
    Lan YL; Zou S; Qin B; Zhu X
    Int Immunopharmacol; 2024 May; 133():112045. PubMed ID: 38615384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive exploration of tumor mutational burden and immune infiltration in diffuse glioma.
    Kang K; Xie F; Wu Y; Wang Z; Wang L; Long J; Lian X; Zhang F
    Int Immunopharmacol; 2021 Jul; 96():107610. PubMed ID: 33848908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of an Immunologic Signature of Lung Adenocarcinomas Based on Genome-Wide Immune Expression Profiles.
    Ling B; Ye G; Zhao Q; Jiang Y; Liang L; Tang Q
    Front Mol Biosci; 2020; 7():603701. PubMed ID: 33505988
    [No Abstract]   [Full Text] [Related]  

  • 13. Mining TCGA database for genes of prognostic value in glioblastoma microenvironment.
    Jia D; Li S; Li D; Xue H; Yang D; Liu Y
    Aging (Albany NY); 2018 Apr; 10(4):592-605. PubMed ID: 29676997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of TNFSF14 on prognosis and immune microenvironment in clear cell renal cell carcinoma.
    Xu F; Guan Y; Zhang P; Xue L; Yang X; Gao K; Chong T
    Genes Genomics; 2020 Sep; 42(9):1055-1066. PubMed ID: 32725578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Analysis and in vitro Experiments of Signatures and Prognostic Value of Immune Checkpoint Genes in Colorectal Cancer.
    Ma R; Qu X; Che X; Yang B; Li C; Hou K; Guo T; Xiao J; Liu Y
    Onco Targets Ther; 2021; 14():3517-3534. PubMed ID: 34103942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune microenvironments differ in immune characteristics and outcome of glioblastoma multiforme.
    Zhang B; Shen R; Cheng S; Feng L
    Cancer Med; 2019 Jun; 8(6):2897-2907. PubMed ID: 31038851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Immune Cell Infiltration and Immune-Related Genes in the Tumor Microenvironment of Glioblastomas.
    Huang S; Song Z; Zhang T; He X; Huang K; Zhang Q; Shen J; Pan J
    Front Immunol; 2020; 11():585034. PubMed ID: 33193404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel Foxp3-related immune prognostic signature for glioblastoma multiforme based on immunogenomic profiling.
    Guo XY; Zhang GH; Wang ZN; Duan H; Xie T; Liang L; Cui R; Hu HR; Wu Y; Dong JJ; He ZQ; Mou YG
    Aging (Albany NY); 2021 Jan; 13(3):3501-3517. PubMed ID: 33429364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SAA1 Expression as a Potential Prognostic Marker of the Tumor Microenvironment in Glioblastoma.
    Cao K; Jiang X; Wang B; Ni Z; Chen Y
    Front Neurol; 2022; 13():905561. PubMed ID: 35756918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of immunobiologic markers in primary and recurrent glioblastoma.
    Rahman M; Kresak J; Yang C; Huang J; Hiser W; Kubilis P; Mitchell D
    J Neurooncol; 2018 Apr; 137(2):249-257. PubMed ID: 29302887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.